Stimulants: Effects, Dependence and Treatment

This page covers what defines a stimulant, how prescribed and illicit stimulants differ, what sustained use does to the brain's reward system, what withdrawal involves, and how stimulant use disorder is treated.

Key Takeaways

• Stimulants raise synaptic dopamine and norepinephrine. Cocaine blocks reuptake; amphetamines both block reuptake and force release, which is why their effects last longer.
• There is no FDA-approved medication for stimulant use disorder, which is the single largest difference between treating stimulant dependence and treating alcohol or opioid dependence.
• Contingency management has the strongest evidence base of any intervention for stimulant use disorder.
• Stimulant withdrawal is psychologically punishing rather than medically dangerous, which causes both the person and the people around them to underestimate it.
• Methamphetamine was involved in 49% of Montana overdose deaths in 2024, more than any other drug, according to CDC National Center for Health Statistics data.

What are stimulants?

Stimulants are drugs that increase central nervous system activity by raising synaptic concentrations of dopamine and norepinephrine. The class produces alertness, elevated mood, suppressed appetite, raised heart rate and raised blood pressure, whether the drug is prescribed or illicit.

The drugs in this class are usually discussed separately, and separating them obscures how much they share. Methamphetamine and cocaine differ substantially in duration and in the harm they cause to specific organs. Methamphetamine and cocaine act through the same neurotransmitter systems, produce the same reorganization of motivation, and end in a withdrawal that follows the same shape.

One feature of stimulant dependence sets it apart from alcohol and opioid dependence and causes it to be persistently underestimated. Stimulant withdrawal produces no medical emergency. Stimulant withdrawal produces exhaustion, flattened mood and craving, none of which look like a crisis from outside, and all of which reliably return people to use.

5 stimulant groups most commonly encountered in clinical practice, grouped by regulatory status:

• Prescribed amphetamines, including dextroamphetamine and mixed amphetamine salts, used to treat attention-deficit hyperactivity disorder and narcolepsy
• Prescribed methylphenidate, used for the same indications through a different mechanism
• Methamphetamine, a highly lipophilic amphetamine derivative that crosses into the brain rapidly
• Cocaine, a plant-derived reuptake inhibitor with a notably short duration of action
• Prescribed weight-management stimulants and a range of novel synthetic cathinones sold in unregulated markets

Two mechanisms distinguish members of the class and explain most of the difference between them. Cocaine blocks the reuptake transporters that clear dopamine from the synapse, so dopamine already released stays present longer. Amphetamines block reuptake and additionally force dopamine out of storage vesicles into the synapse, which produces a larger and considerably more sustained rise.

That mechanistic difference produces the practical one. Cocaine's effect lasts minutes to around an hour, which drives repeated dosing in short cycles. Methamphetamine's effect lasts many hours, which drives binges that continue for days. The comparison between prescribed and illicit amphetamines is examined on the page on meth vs Adderall.

What is the difference between prescription and illicit stimulants?

Prescription and illicit stimulants act on the same receptors. They differ in dose control, route of administration, speed of onset and purity, and those four differences account for the difference in addiction risk rather than any difference in the underlying pharmacology.

Speed of onset is the most important of the four. The reinforcing power of a stimulant tracks how rapidly synaptic dopamine rises, not how high it eventually gets. A prescribed oral stimulant taken as directed produces a gradual rise over roughly an hour. The same class of drug smoked or injected produces a near-immediate spike, and that spike is what the reward system encodes as worth repeating.

Dose control follows. A prescribed tablet contains a known quantity, dispensed on a schedule set by a prescriber who is monitoring effect and side effects. Illicit stimulants carry no reliable dose information, and increasingly carry contaminants, including fentanyl, which is the subject of the page on fentanyl and why it is so dangerous.

Purity is the fourth difference and the one that has changed most in recent years. Illicitly manufactured methamphetamine is now produced at high purity through industrial synthesis rather than in small improvised laboratories, which has raised potency while lowering price. The consequence appears directly in mortality data rather than in prevalence data.

What do stimulants do to the brain's reward system?

Stimulants flood the mesolimbic dopamine pathway with far more dopamine than any natural reward produces. The brain responds by reducing dopamine receptor density and dopamine production, which leaves ordinary rewards muted and the drug increasingly required to feel normal rather than good.

The mesolimbic pathway evaluates what is worth pursuing. It responds to food, social contact, sex and achievement by releasing dopamine in proportion to how unexpectedly good an outcome was, which is how motivation gets allocated. Stimulants bypass that proportionality entirely and produce a dopamine signal an order of magnitude beyond anything the system evolved to process.

Downregulation follows. The brain protects itself against sustained overstimulation by reducing the number of available dopamine receptors and lowering its own dopamine output. Two consequences follow directly from that adaptation, and together they define stimulant dependence:

• Tolerance: the same quantity produces progressively less effect, so intake escalates
• Anhedonia: natural rewards stop registering, because the receptors that would have registered them have been reduced

Anhedonia is the more consequential of the two and the more often missed. A person in early stimulant recovery is not merely resisting a craving. They are living in a period during which food, company, music and accomplishment produce little of the response they used to produce, and during which the drug is the only reliable route to feeling anything. Receptor density recovers over months, and the gap between how long that takes and how long motivation can be sustained without reward is where most returns to use happen.

Sustained heavy use adds physical harm on top of this. Methamphetamine damages dopamine and serotonin nerve terminals, and meth addiction brings dental and skin damage as well.

Cocaine addiction brings its own damage to the heart and the nose.

What is stimulant withdrawal like and how long does it last?

Stimulant withdrawal produces exhaustion, excessive sleep, increased appetite, depressed mood, agitation and intense craving. It begins within 24 hours of the last dose, is most severe over the first 7 to 10 days, and is psychologically punishing rather than medically dangerous.

The sequence has three recognizable phases. The crash occupies the first day or two and consists of overwhelming fatigue and prolonged sleep as the person recovers from a period of sleep deprivation. The acute withdrawal phase runs across roughly the first one to two weeks, with low mood, anhedonia, poor concentration, irritability and heavy craving. Protracted symptoms then persist at lower intensity for weeks to months while receptor density recovers.

The comparison with alcohol and benzodiazepines is the point that most changes clinical handling. Alcohol withdrawal and benzodiazepine withdrawal can kill, and they require medical supervision on that basis. Stimulant withdrawal does not produce seizures or autonomic instability, and a person going through it is not in medical danger from the withdrawal itself.

If a person going through stimulant withdrawal expresses suicidal thoughts, that is a medical emergency. Call or text 988 to reach the Suicide and Crisis Lifeline, or call 911.

The absence of a physical crisis also shapes what treatment can offer, because the medications that manage alcohol and opioid withdrawal have no counterpart here.

How is stimulant use disorder treated?

Stimulant use disorder is treated with behavioral interventions rather than medication, because no medication holds FDA approval for the condition. Contingency management has the strongest evidence base, supported by cognitive behavioral therapy, community reinforcement and structured treatment settings.

This is the defining difference between stimulant treatment and the treatment of alcohol or opioid use disorder. Alcohol use disorder has three approved medications. Opioid use disorder has three, and their association with reduced mortality is well established. Stimulant use disorder has none, and a treatment program that describes medication-assisted treatment for stimulants is describing something that does not exist.

Contingency management fills that gap more effectively than anything else studied. It provides tangible reinforcement, typically vouchers or prizes, contingent on verified stimulant-negative urine samples. The rationale follows directly from the pharmacology. Supplying immediate, reliable, external reinforcement addresses the mechanism rather than working around it, where the disorder consists of a reward system that has stopped responding to ordinary reinforcement.

Cognitive behavioral therapy addresses the situations, cues and thinking that precede use, and stimulant cues are unusually powerful because stimulant use is so strongly tied to specific settings and routines. Residential treatment contributes the element behavioral therapy alone cannot, which is physical separation from supply and from cues during the weeks when anhedonia is deepest and craving is highest.

No medication holds FDA approval for stimulant use disorder, and two investigational approaches carry the strongest signal. Trivedi and colleagues reported in the ADAPT-2 trial that extended-release naltrexone combined with bupropion reduced methamphetamine use against placebo, and that combination remains off-label. Repetitive transcranial magnetic stimulation has accumulated trial evidence for craving reduction, and it remains investigational for this indication.

Clinicians score withdrawal severity with the Stimulant Selective Severity Assessment, the instrument Walker and colleagues extended from the cocaine version, which rates symptoms including lethargy, sleep change, appetite change and craving.

Montana's stimulant burden is the largest of any drug category in the state. CDC National Center for Health Statistics data show methamphetamine involved in 49% of Montana overdose deaths in 2024, more than any other drug. Montana DPHHS recorded stimulant-involved overdose deaths rising from 3.1 to 8.2 per 100,000 residents between 2014 and 2023, with methamphetamine accounting for effectively all of that increase. The full state picture is on the page on addiction in Montana.

Frequently asked questions

Sources

1. American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Stimulant use disorder criteria and severity thresholds.
2. Montana Department of Public Health and Human Services (2024). Drug Overdose Deaths in Montana 2014-2023. Stimulant and methamphetamine overdose death rates by year.
3. Centers for Disease Control and Prevention, National Center for Health Statistics. Montana state overdose data, 2024. Methamphetamine share of Montana overdose deaths.
4. Centers for Disease Control and Prevention (2025). Drug Overdose Deaths Involving Stimulants, United States, January 2018 to June 2024, Morbidity and Mortality Weekly Report, Volume 74. National stimulant mortality trends.
5. National Institute on Drug Abuse. Research on psychostimulant pharmacology and on contingency management for stimulant use disorder.
6. Trivedi, M. H. et al. (2021). Bupropion and Naltrexone in Methamphetamine Use Disorder, New England Journal of Medicine, 384(2), 140-153. The ADAPT-2 trial of extended-release naltrexone with bupropion.
7. Walker, R. et al. (2019). The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment, Substance Use and Misuse, 54(3), 351-361. Scoring of stimulant withdrawal severity.
8. Amerio, A. et al. (2023). Effects of transcranial magnetic stimulation on cocaine addiction: A systematic review of randomized controlled trials, Psychiatry Research, 329, 115491. Evidence status of rTMS as an adjunctive treatment.